Izabela Pera Calvi

Izabela Pera Calvi

Auto-generated profile, based on publicly available information

Izabela Pera Calvi

Division of Medicine, Immanuel Kant Baltic Federal University, Kaliningrad, Russia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
YMYasmin Luz Lima de Mesquita
Yasmin Luz Lima de Mesquita
ICIzabela Pera Calvi
Izabela Pera Calvi
IMIsabela Reis Marques
Isabela Reis Marques
SCSara Almeida Cruz
Sara Almeida Cruz
EPEduardo Messias Hirano Padrao
Eduardo Messias Hirano Padrao
VRVladimir Vitalievich Rafalskiy
Vladimir Vitalievich Rafalskiy

4 June 2023 in Hernia
Verified
Journal Article
Closed access
PDF file
MBMarina Mordehachvili Burlá
Marina Mordehachvili Burlá
CGC. P. Gomes
C. P. Gomes
ICI. Calvi
I. Calvi
EOE. S. C. Oliveira
E. S. C. Oliveira
DHDavid Abraham Batista da Hora
David Abraham Batista da Hora
RLRichard Lu
Richard Lu

6 September 2022 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
IMIsabela R. Marques
Isabela R. Marques
ICIzabela P. Calvi
Izabela P. Calvi
SCSara A. Cruz
Sara A. Cruz
LSLuana M. F. Sanchez
Luana M. F. Sanchez
IBIsis F. Baroni
Isis F. Baroni
PMPaula C. Mari
Paula C. Mari

22 August 2024 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
RMRafaela de Moraes-Souza
Rafaela de Moraes-Souza
RCRegina Chahine Chater
Regina Chahine Chater
ICIzabela Pera Calvi
Izabela Pera Calvi
YMYasmin Mesquita
Yasmin Mesquita
RSRubiana Sarto
Rubiana Sarto
PHPedro Herranz-Pinto
Pedro Herranz-Pinto
Background and Objective Plaque psoriasis is commonly treated topically with glucocorticoids and vitamin D derivatives. However, potential side effects such as skin atrophy underscore the need for safe and effective alternative topical therapies. Recently, the US Food and Drug Administration (FDA) and Health Canada approved roflumilast 0.3% cream as an option for treating this disease. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of topical roflumilast 0.3% compared with vehicle for plaque psoriasis. Methods PubMed, Embase, ClinicalTrials.gov, and Cochrane databases were searched from inception to 1 May 2024, assessing the outcomes of Investigator’s Global Assessment (IGA) or body-IGA success (clear or almost clear status plus an at least 2-grade improvement from baseline), Psoriasis Area and Severity Index (PASI)-50, PASI-75, PASI-90, intertriginous-IGA success (clear or almost clear status on the intertriginous-IGA plus an at least 2-grade improvement from baseline), and adverse events (AEs). Statistical analysis was performed using Review Manager, R software, and RStudio. Heterogeneity was determined using the Cochran Q test and I2 statistics. Results Four RCTs were included, comprising a total of 1403 patients, of whom 885 (63.1%) received topical roflumilast 0.3% and 518 (36.9%) received vehicle. At week 8, the achievement of IGA or body-IGA success was significantly higher among those treated with topical roflumilast than in the vehicle group [relative risk (RR) 5.07; 95% confidence interval (CI) 3.55–7.23; p < 0.01]. Similar findings were observed at week 8 for PASI-50 (RR 2.73; 95% CI 2.27–3.29; p < 0.01), PASI-75 (RR 4.48; 95% CI 2.26–8.89; p < 0.01), and PASI-90 (RR 5.61; 95% CI 2.57–12.25; p < 0.01). Corresponding outcomes were found at weeks 2, 4, and 6. Additionally, a higher percentage of patients treated with topical roflumilast 0.3% once daily achieved intertriginous-IGA success, compared with those receiving vehicle, at week 8 (71.9% versus 20.5%; RR 3.32; 95% CI 2.11–5.22; p < 0.01), with similar findings at weeks 2, 4, and 6. While a significant difference was observed in the overall incidence of AEs between the topical roflumilast and vehicle groups, there was no difference in treatment-related AEs, serious AEs, or AEs leading to study discontinuation. Conclusion These findings support the superiority of topical roflumilast 0.3% over vehicle and suggest its use as a valuable asset for the treatment of plaque psoriasis. Protocol registration International Prospective Register of Systematic Reviews (PROSPERO), CRD42023456494.


7 November 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
MBMarina Mordehachvili Burlá
Marina Mordehachvili Burlá
ICIzabela Pera Calvi
Izabela Pera Calvi
RCRegina Chahine Chater
Regina Chahine Chater
RMRafaela de Moraes‐Souza
Rafaela de Moraes‐Souza
VRVladimir Vitaliy Rafalskiy
Vladimir Vitaliy Rafalskiy
RHRoger Haber
Roger Haber